Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China
The clinical spectrum of GAD65 neurological autoimmunity appeared highly diverse. Immunotherapy can benefit the majority of patients, and early treatment appeared to be associated with good prognosis. RTX may be more effective than MMF; however, this requires more rigorous prospective studies to explore.
Authors
- Sun Ying (ORCID: https://orcid.org/0000-0003-4052-2498)
- Junwei Hao (ORCID: https://orcid.org/0000-0002-3075-5434)
- Yue Hou (ORCID: https://orcid.org/0000-0002-5040-9344)
- Junhua Liang (ORCID: https://orcid.org/0000-0001-6598-5507)
- Lehong Gao
- Xu Fang (ORCID: https://orcid.org/0000-0001-5795-9843)
- Mengyao Zhang (ORCID: https://orcid.org/0000-0002-8353-7465)
- Liang Liu (ORCID: https://orcid.org/0000-0002-7654-2223)
- Dawei Li (ORCID: https://orcid.org/0000-0002-1094-9282)
- Huiqing Dong (ORCID: https://orcid.org/0000-0002-7023-8343)
- Jia Chen (ORCID: https://orcid.org/0000-0003-0080-0748)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-4168-6702)
- Li Di (ORCID: https://orcid.org/0000-0001-6117-9022)
- Qing Xue (ORCID: https://orcid.org/0009-0008-1572-3224)
- Yan Han (ORCID: https://orcid.org/0000-0002-2881-1601)
- Yue Han (ORCID: https://orcid.org/0000-0002-6015-7267)
- Chunqiu Fan (ORCID: https://orcid.org/0009-0001-3788-9195)
- Zhandong Qiu
- Xixi Yang
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/cns.70237
- Citations
- 4
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.56